How did Matinas Biopharma's operating expenses trend in Q3 2024?

Matinas Biopharma's operating expenses for Q3 2024 are not currently available. However, the company's recent financial actions and trends in Q2 2024 provide insights into its financial management.

1. **Reverse Stock Split and Authorized Share Reduction**: Matinas Biopharma implemented a reverse stock split at a ratio of one-for-fifty, effective August 30, 2024. This move was accompanied by a reduction in authorized shares from 500 million to 250 million. Such a strategic adjustment in capital structure can sometimes be a cost-saving measure, as it reduces the number of outstanding shares and potentially lowers administrative expenses related to shareholding.
2. **Net Loss Improvement and Cash Position**: The company reported a net loss of $5.7 million for Q2 2024, an improvement from the previous year's loss of $6.1 million. This slight improvement in financial performance could indicate a positive trend in cost management. Additionally, Matinas Biopharma maintained a stable cash position with $14.3 million in cash and securities as of June 30, 2024, compared to $13.8 million as of December 31, 2023.
3. **Global Partnership and Clinical Trial Progress**: Matinas Biopharma is finalizing a global partnership for its antifungal medication, MAT2203, and is advancing its ORALTO Phase 3 registration trial. These developments suggest a forward-looking trajectory for the company, with potential revenue streams and clinical trial-related expenses that could impact future operating expenses.

In conclusion, while specific Q3 2024 operating expenses are not available, the company's reverse stock split, improved net loss position, and strategic developments in drug partnerships and clinical trials suggest a focused approach to cost management and a positive trajectory for the company's financial performance.